东南亚头颈癌:2022年发病率、死亡率及至2050年的预测
该研究基于2022年全球癌症观察站11个东南亚国家的数据,分析唇及口腔、唾液腺、口咽、鼻咽、下咽、喉和甲状腺癌的年龄标化发病率和死亡率,并基于人口变化预测至2050年。结果显示东南亚头颈癌总体年龄标化发病率(18.0)与全球(18.9)相当,但年龄标化死亡率显著更高(9.5 vs. 5.3)。
要点
- 缅甸口腔癌年龄标化发病率男性6.6、女性2.6,年龄标化死亡率男性3.9、女性1.6。
- 文莱和印度尼西亚男性鼻咽癌年龄标化发病率分别为9.8和9.6,超过全球平均水平。
- 预测至2050年印度尼西亚新增男性病例47,000例、女性28,200例,男性死亡30,600例、女性12,200例。
核心结论
- 东南亚头颈癌负担上升,发病和死亡率存在显著差异,需针对性预防、早期发现和癌症照护系统投入。
研究设计与样本
- 基于人群的分析,使用2022年全球癌症观察站11个东南亚国家的数据。
- 分析唇及口腔、唾液腺、口咽、鼻咽、下咽、喉和甲状腺癌。
- 年龄标化发病率和死亡率采用Segi-Doll世界标准计算。
- 至2050年的预测基于联合国世界人口展望数据的人口变化,假设发病率和死亡率稳定。
主要发现
- 缅甸口腔癌年龄标化发病率男性6.6、女性2.6,年龄标化死亡率男性3.9、女性1.6。
- 印度尼西亚、菲律宾和新加坡唾液腺癌发病率升高。
- 缅甸口咽癌男性显著占优,年龄标化发病率男女比为10:1。
- 文莱和印度尼西亚男性鼻咽癌年龄标化发病率分别为9.8和9.6,超过全球平均水平。
- 预测至2050年印度尼西亚新增男性病例47,000例、女性28,200例,男性死亡30,600例、女性12,200例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterize the incidence, mortality, and disparities in head and neck cancer (HNC) across Southeast Asia (SEA) in 2022 and project trends to 2050 to inform cancer planning. METHODS: We conducted a population-based analysis using 2022 Global Cancer Observatory data from 11 SEA countries. We analyzed cancers of the lip and oral cavity, salivary glands, oropharynx, nasopharynx, hypopharynx, larynx, and thyroid. Age-standardized incidence and mortality rates (ASIR and ASMR) were calculated using the Segi-Doll world standard. Projections to 2050 were based on demographic changes using UN World Population Prospects data, assuming stable incidence and mortality rates. RESULTS: Myanmar had the highest oral cancer rates (ASIR: 6.6 males, 2.6 females; ASMR: 3.9 males, 1.6 females). Elevated salivary gland cancer incidence was observed in Indonesia, the Philippines, and Singapore. Oropharyngeal cancers showed strong male predominance in Myanmar (ASIR ratio: 10:1). Nasopharyngeal cancer incidence in Brunei and Indonesia exceeded global averages (ASIR: 9.8 and 9.6 males). Projections to 2050 estimate 47,000 new male cases and 28,200 new female cases in Indonesia, with 30,600 male deaths and 12,200 female deaths. While SEA's overall ASIR for HNC (18.0) was comparable to the global average (18.9), the ASMR was significantly higher (9.5 vs. 5.3). CONCLUSIONS: The rising burden of HNC in SEA highlights urgent disparities in incidence and mortality. Targeted prevention, early detection, and investment in cancer care systems are essential to mitigate future disease burden and improve outcomes. LEVEL OF EVIDENCE: Level III-Epidemiologic study using population-based registry data.
引用
- Chen J, Selokar A, Ho FDV, et al. Head and Neck Cancer in Southeast Asia: 2022 Incidence, Mortality, and Projections to 2050. Laryngoscope. 2025. PMID: 40698853. doi:10.1002/lary.32450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。